TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $15 from $13 and keeps a Buy rating on the shares. The firm said they posted good results and noted guidance was raised and still see room for upside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies price target raised to $14 from $10 at JPMorgan
- Adaptive Biotechnologies Reports Strong Q2 2025 Growth
- Adaptive Biotechnologies: Strong Financial Performance and Strategic Initiatives Drive Optimistic Outlook
- Adaptive Biotechnologies reports Q2 EPS (17c), consensus (24c)
- COIN, BMNR, RBLX: Cathie Wood Buys Over $54M of Crypto Stocks, Dumps Roblox Stake